Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

103
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
103
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

574
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
574
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

487
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
487
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

52
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
52
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

151
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
151

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IgE and cardiac disease.

Acta physiologica (Oxford, England)·2025
Same author

Cellular metabolism of substance P produces neurokinin-1 receptor peptide agonists with diminished cyclic AMP signaling.

American journal of physiology. Cell physiology·2024
Same author

Replacement of Lost Substance P Reduces Fibrosis in the Diabetic Heart by Preventing Adverse Fibroblast and Macrophage Phenotype Changes.

Cells·2021
Same author

The Histamine 3 Receptor Is Expressed in the Heart and Its Activation Opposes Adverse Cardiac Remodeling in the Angiotensin II Mouse Model.

International journal of molecular sciences·2020
Same author

The Diabetic Cardiac Fibroblast: Mechanisms Underlying Phenotype and Function.

International journal of molecular sciences·2020
Same author

Regulation of Cardiac Mast Cell Maturation and Function by the Neurokinin-1 Receptor in the Fibrotic Heart.

Scientific reports·2019

Related Experiment Video

Updated: Oct 17, 2025

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

11.4K

Histamine receptors in heart failure.

Scott P Levick1,2

  • 1Kolling Institute, St Leonards, Australia. scott.levick@sydney.edu.au.

Heart Failure Reviews
|October 8, 2021
PubMed
Summary

Histamine receptors play complex roles in heart failure. Targeting these receptors, particularly histamine 1 and 2, offers potential therapeutic strategies for heart conditions.

Keywords:
CardiomyopathyHeart failureHistamineHistamine receptorsMast cell

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K
Isolation of Functional Cardiac Immune Cells
07:26

Isolation of Functional Cardiac Immune Cells

Published on: December 5, 2011

15.2K

Related Experiment Videos

Last Updated: Oct 17, 2025

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

11.4K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K
Isolation of Functional Cardiac Immune Cells
07:26

Isolation of Functional Cardiac Immune Cells

Published on: December 5, 2011

15.2K

Area of Science:

  • Cardiology
  • Pharmacology
  • Molecular Biology

Background:

  • Histamine, a biogenic amine, mediates diverse physiological effects through four G-protein-coupled receptors.
  • Histamine receptors (H1R, H2R, H3R, H4R) significantly influence cardiac function and remodeling.
  • Their roles in heart failure are complex, with H1R and H2R often exhibiting detrimental effects.

Purpose of the Study:

  • To review the signaling pathways and functions of histamine receptors in normal cardiac physiology.
  • To detail the known roles of histamine receptors in adverse cardiac remodeling and heart failure.
  • To highlight the therapeutic potential of targeting histamine receptors for heart failure treatment.

Main Methods:

  • Review of existing clinical studies and experimental animal models.
  • Analysis of histamine receptor signaling mechanisms in cardiac cells (cardiomyocytes, fibroblasts, endothelial cells).
  • Examination of the effects of histamine receptor activation/blockade on cardiac function and remodeling.

Main Results:

  • Histamine 1 receptor activation shows detrimental effects, primarily in the coronary vasculature.
  • Histamine 2 receptor activation is linked to adverse cardiac remodeling.
  • Histamine 3 receptor activation suggests protective roles, while Histamine 4 receptor's role remains largely unknown.

Conclusions:

  • Histamine receptors are critical players in the pathophysiology of heart failure.
  • Targeting specific histamine receptors presents a promising avenue for heart failure drug repurposing and development.
  • Further research into H3R and H4R functions in heart failure is warranted.